ATMP Sweden is a national coordination and communication network that aims to increase patient access to safe and effective medicines based on recombinant genes, living cells, and/or tissue engineering. This innovative category of drugs is referred to as Advanced Therapy Medicinal Products (ATMPs) by the European Medicines Agency. By coordinating efforts and promoting communication, ATMP Sweden aims to facilitate the development and accessibility of these advanced therapies to enhance patient care.
In Flemingsberg, there is a history of successful research and clinical development, particularly in the field of advanced therapies and regenerative medicine. The progress holds promise for effective treatments for previously incurable heart diseases, various forms of cancer, as well as a range of autoimmune diseases such as diabetes, Parkinson’s, and Alzheimer’s. These new approaches lead to more successful treatments, making ATMP Sweden a highly valuable network in Flemingsberg.
Karolinska Institutet also has an ATMP center that consolidates the development of cell, gene, and tissue therapy within one organization. They also participate in national and international collaborations.
Learn more about ATMP Sweden here
Learn more about ATMP in Flemingsberg here